2005 African American Heart Failure Symposium

Saturday, Jan. 8, 2005
7:30 a.m. to 1 p.m.
Hilton Jacksonville Riverfront

Major Medical Breakthrough in Heart Failure Treatment

Presented by the University of Florida Division of Cardiology
Jacksonville, Fla.
Nov. 29, 2004

Dear Colleague:

I would like to invite you to an exciting continuing medical education symposium that will be held in Jacksonville, Fla., on Saturday, Jan. 8, 2005.

We have just completed a major clinical trial to test the hypothesis that using a therapy designed to provide enhancement of nitric oxide delivery to myocardial cells would be of clinical benefit in African Americans with severe advanced systolic heart failure. The African American Heart Failure Trial, or A-HeFT, has demonstrated a significant reduction in the composite endpoint of mortality, hospitalization and quality of life in African Americans assigned to therapy with a combination of hydralazine and isosorbide nitrate.

The basis of the study is that compared to Caucasians, nitric oxide formation is reduced in African Americans with heart failure. This trial, one of the first to target a specific demographic group in heart failure, has demonstrated that the addition of nitric oxide enhancing therapy to standard medical therapy for chronic, severe heart failure will improve outcomes in African Americans with the disease. This breakthrough trial was presented at the American Heart Association’s annual meeting in New Orleans earlier this month.

Our faculty will include Clyde Yancy, MD, member of the A-HeFT steering committee, Peter Carson, MD, chair of the A-HeFT endpoint committee, Christopher O’Connor, MD, member of the endpoint committee, and myself, also a member of the endpoint committee.

Sponsored by the University of Florida, the symposium will provide trial data that represents a substantial breakthrough in heart failure treatment. This is an opportunity to hear from heart failure experts information that takes heart failure therapy in an entirely new direction.

Please register as soon as possible as space is limited. I look forward to seeing you at this important symposium.

With personal regards,

Alan B. Miller, MD
Professor of Medicine
University of Florida Jacksonville
Heart Failure Treatment of African Americans: 
Impact of New Nitric Oxide Enhancing Therapies

Intended Audience
Primary care and internal medicine physicians, cardiologists, ARNPs, PAs and allied healthcare professionals.

Learning Objectives
At the end of this activity, attendees should be able to:
- Describe the pathophysiology of heart failure and appropriate standard therapies;
- Understand the differences in nitric oxide regulation in African Americans and Caucasians;
- Present the results of nitric oxide enhancing therapy in African Americans with heart failure.

Agenda
7:30 a.m. to 8:30 a.m. Registration, Welcome and Continental Breakfast
8:30 a.m. to 9:10 a.m. Overview of Congestive Heart Failure—Therapies for Systolic Dysfunction presented by Alan B. Miller, MD
9:10 a.m. to 9:50 a.m. The Vasodilator Heart Failure Trials—Lessons on the Differences in Therapies in African Americans presented by Peter Carson, MD
9:50 a.m. to 10:10 a.m. Break
10:10 a.m. to 10:50 a.m. Heart Failure in African Americans—Insights from the Duke Database presented by Christopher O’Connor, MD
10:50 a.m. to 11:30 a.m. New Therapies for African Americans with Heart Failure presented by Clyde Yancy, MD
11:30 a.m. to 12 p.m. Panel Discussion
12 p.m. to 1 p.m. Closing Comments, Lunch and Evaluations

Accreditation
The University of Florida College of Medicine is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

Credit
The University of Florida College of Medicine designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This CME activity is supported by an educational grant from NitroMed, Inc.
Peter Carson, MD, graduated from the University of North Carolina School of Medicine. After an internship at the University of Texas at San Antonio, he completed an internal medicine residency at Case Western Reserve in Cleveland, Ohio. Dr. Carson completed his cardiology fellowship at the University of Minnesota.

He is currently chief of coronary care at the Washington DC Veterans Affairs Medical Center and associate professor of medicine at Georgetown University Hospital. His academic and research interest is heart failure. Dr. Carson has written and lectured extensively on this topic and has served in a leadership role in most major recent heart failure trials, including steering committee member - BEST, PRAISE-2; endpoints committee chair - BEST, VALHeFT, COPERNICUS, A-HeFT; COMPANION, EMOTE; member - PRAISE, VEST, OVERTURE, ESSENTIAL. He is currently co-principal investigator of the I-PRESERVE trial. Dr. Carson has been prominently involved in investigation into heart failure with preserved systolic function and clinical trial event adjudication.

Dr. Carson has spurred interest in the area of racial response in heart failure in his examination of the response of African Americans to vasodilator therapy (hydralazine/isosorbide dinitrate) and ACEI therapy in V-HeFT I and II. He has also been involved in the analysis of racial response to beta blocker in BEST and COPERNICUS.

Dr. Carson is a reviewer for Circulation, the Journal of the American College of Cardiology, the American Journal of Cardiology, the American Heart Journal and the Journal of Cardiac Failure.

Alan B. Miller, MD, graduated from the University of Pittsburgh School of Medicine. He completed his internal medicine internship and one year of medicine residency at Mt. Sinai Medical Center in Cleveland, Ohio. He then served two years in the U.S. Air Force Medical Corps, with a tour in Vietnam. Dr. Miller completed his medicine residency at George Washington University Medical Center in Washington, DC. He returned to Cleveland for a cardiology fellowship at Cleveland Metropolitan General Hospital.

Following his fellowship, Dr. Miller became chief of cardiology at the University of Florida in Jacksonville. Currently, he is a professor of medicine and director of the Heart Failure Clinic at Shands Jacksonville.

Dr. Miller’s research has been in the area of heart failure and coronary artery disease. He has published numerous scientific manuscripts in these areas. He serves as a reviewer and editorial board member for a number of cardiology journals.

Dr. Miller is a fellow of the American College of Cardiology and the Clinical Council of the American Heart Association. He has served as governor of the Florida chapter of the American College of Cardiology and chair of the research committee for the Florida affiliate of the American Heart Association.

Christopher M. O’Connor, MD, FACP, FACC, is a professor of medicine in the division of cardiology, chief of the division of clinical pharmacology and director of the Duke Heart Failure Program at Duke University Medical Center.

His current research is in heart failure, specifically the development of novel therapies for the management of chronic heart failure and ischemic heart disease. Dr. O’Connor’s primary work has been in therapeutic development through the conduct of randomized, controlled clinical trials. He plays a vital role as a principal investigator and steering committee member in many such trials. In addition, Dr. O’Connor utilizes observational databases in his research to characterize the epidemiology of heart failure. The Duke Databank and databases from completed clinical trials have also been approaches used by Dr. O’Connor to answer important clinical questions.

Dr. O’Connor has served as a consultant for the National Heart, Lung and Blood Institute, and the Food and Drug Administration’s Cardiorenal Advisory Panel. He is a member of the editorial boards of numerous respected medical journals and serves as a consultant to several pharmaceutical companies.

He is an internationally recognized expert in the field of cardiology and the treatment of heart failure. Dr. O’Connor has achieved prestigious recognition as a fellow of the American College of Cardiology and the American College of Physicians.

Clyde W. Yancy, MD, FACC, is an associate professor of internal medicine and cardiology at the University of Texas Southwestern Medical Center at Dallas. He received his medical degree from Tulane University School of Medicine and all of his post-graduate training from UT Southwestern Medical Center. Currently, he serves as medical director of the UT Southwestern Medical Center Heart Transplant Program at St. Paul University Hospital. He also holds the directorship of the Cardiovascular Institute at St. Paul University Hospital and oversees the Heart Failure Program and co-directs the Pulmonary Hypertension Program within the institute. He was recently named associate dean of clinical affairs at St. Paul University Hospital.

Dr. Yancy is broadly published in the areas of heart failure and heart transplantation, and is recognized for his work in hypertension and pulmonary hypertension. He is an active member in the American College of Cardiology, Association of Black Cardiologists, American Heart Association, Heart Failure Society of America, American Society of Hypertension and the International Society of Heart and Lung Transplantation. He is a fellow of the American College of Cardiology.

Dr. Yancy serves as associate editor for Congestive Heart Failure and the Journal of Cardiac Failure. He is a reviewer for all of the major journals in cardiovascular medicine. Within the Heart Failure Society of America, he has served as an ex-officio member of the executive committee for three years and is currently chair of the membership committee. Dr. Yancy has chaired the American Heart Association’s Heart Failure and Transplantation Subcommittee of the Council on Clinical Cardiology and is the national spokesperson for the association’s medical editorial board of HeartProfilers, a Web-based patient education program.

He is a consultant to the Centers for Disease Control and a member of the Food and Drug Administration’s Cardiovascular Device Panel. In 2003, Dr. Yancy was named National Physician of the Year by the American Heart Association for leadership in programs related to the association’s mission.
Heart Failure Treatment of African Americans:
Impact of New Nitric Oxide Enhancing Therapies

Saturday, Jan. 8, 2005
Hilton Jacksonville Riverfront
1201 Riverplace Blvd., Jacksonville, Fla.


Three ways to register
Online: www.hscj.ufl.edu/cme
Fax: (904) 244-3898
Mail: Barbara Jones
UF CME Office
653 W. Eighth St.
Jacksonville, FL 32209

Participant Information
Name: ________________________________
Title/Credentials: ______________________
Organization: _________________________
Address: ______________________________
City/State/Zip: _________________________
Home Phone: ___________________________
Work Phone: __________________________
Fax: _________________________________
E-mail: ______________________________
I prefer to receive registration confirmation via (circle one): E-mail Fax

Hilton Jacksonville Riverfront
The symposium will be held in the Hilton Jacksonville Riverfront’s Duval Ballroom. The Hilton is conveniently located in downtown Jacksonville on the Southbank of the St. John’s River. The hotel sits near the Main Street Bridge on Riverplace Boulevard. For directions and additional hotel information, visit www.jacksonvillehilton.com.

Parking
Complimentary self-parking is available at the hotel. Valet parking is $12 a day.

Accommodations
The single/double room rate is $89 per night. A limited number of rooms are available at this rate, so register early by calling the hotel directly at (904) 398-8800 ext. 4027 or toll-free at (800) 445-8667 before 5 p.m. on Dec. 22. Be sure to mention that you’re attending the University of Florida Heart Failure Symposium. This special rate is not guaranteed after Dec. 22.

For Persons with Disabilities
Individuals with disabilities requiring special accommodations should contact Barbara Jones at (904) 244-2380 a minimum of seven days prior to the program so that proper consideration may be given to the request.